Researchers found that Intravacc, a leading vaccine development and manufacturing organization, has been approved by the French Ministry of Higher Education, Research, and Space for the Crédit d’Impôt Recherche (CIR) program for the years 2025 to 2027. This approval allows French biotech and pharmaceutical companies to access Intravacc’s services for vaccine development, analytical development, and compliant manufacturing, making it easier for them to claim eligible research and development (R&D) expenses.

This development is significant for anyone interested in health and longevity, as it could lead to faster and more efficient vaccine innovations. With Intravacc’s expertise in various vaccine types—including viral, bacterial, and protein vaccines—French companies can enhance their R&D efforts. This means that in the coming years, you might see more effective vaccines being developed, which could improve overall public health and potentially lead to better health outcomes as we age.

The evidence supporting this approval is based on Intravacc’s established capabilities and the French government’s recognition of its role as a private research institution. While this is a positive step, it’s important to note that the actual impact of these developments on vaccine availability and effectiveness will depend on the projects undertaken and their success in clinical trials.

If you’re interested in supporting vaccine innovation, staying informed about new developments in vaccine research and considering vaccination as a key part of your health strategy can be beneficial. Engaging with healthcare providers about the latest vaccines and their benefits can also help you make informed decisions about your health as you age.

Source: globenewswire.com